Drug Trial Radar · NCT01262677
Once-A-Day Pregabalin For Partial Seizures
Last checked: Nov 20, 2026Latest source record: Jan 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
325
Actual
Start
Feb 17, 2011
Primary completion
Jul 31, 2012
Study completion Aug 1, 2012
Sponsor
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
- Sponsor type
- Industry
- First posted
- Dec 17, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Approximately 30% percent of subjects with partial seizures are refractory to treatment with single or combination antiepileptic drugs. The present study will compare the efficacy of two different dosages of pregabalin CR dosed once daily as compared to placebo, when used as adjunctive therapy in subjects requiring adjunctive therapy for partial onset epilepsy, using a randomized, parallel group design.
Conditions
- Partial Seizures
- Epilepsies, Partial
Interventions
pregabalinDrug
Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days
pregabalinDrug
Controlled Release Tablets, 165 mg, once per day (QD) for 11 days
pregabalinDrug
Controlled Release Tablets, 330 mg, once per day (QD) for the remainder of the double-blind treatment phase (max is 12 weeks)
pregabalinDrug
Controlled Release Tablets, 165 mg, once per day (QD) for 7 days
pregabalinDrug
Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days
pregabalinDrug
Controlled Release Tablets, 165 mg, once per day (QD) for the remainder of the up-titration and double-blind treatment and taper phases (max 14.5 weeks)
placeboDrug
matched to the active drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Log Transformed (Loge) 28-day Seizure Rate for All Partial Onset Seizures During the Double-blind Treatment PhaseTime frame: Week 0 to Week 14
Locations
82 sites in 18 countries. Site status is shown where the registry gives one.
Neurology Clinic, PC
Northport, Alabama
NEA Baptist Clinic
Jonesboro, Arkansas
Clinical Trials, Inc.
Little Rock, Arkansas
Collaborative Neuroscience Network, Inc.
Long Beach, California
Viking Clinic Research Center
Murrieta, California
Viking Clinical Research Center
Murrieta, California
Neurological Research Institute
Santa Monica, California
Viking Clinical Research Center
Temecula, California
Sarkis Clinical Trials
Gainesville, Florida
Optima Neurological Services, LLC
Gainesville, Florida
Sleep Disorders Center of Georgia - Gainesville
Gainesville, Georgia
Southern Illinois University School of Medicine
Springfield, Illinois
VCMA Comprehensive Epilepsy Center
Wichita, Kansas
Via Christi Research
Wichita, Kansas
Associates in Neurology, PSC
Lexington, Kentucky
Mid Atlantic Headache Institute
Pikesville, Maryland
Asheville Neurology Specialists, PA
Asheville, North Carolina
Lynn Health Science Institute
Oklahoma City, Oklahoma
Mark A. Fisher, M.D.- Private Practice
Oklahoma City, Oklahoma
Sooner Clinical Research
Oklahoma City, Oklahoma
Veroniqe Sebastian, MD
Oklahoma City, Oklahoma
Angelique Barreto, MD
Oklahoma City, Oklahoma
University of Pennsylvania
Philadelphia, Pennsylvania
FutureSearch Trials of Neurology
Austin, Texas
Scott and White Healthcare-Office of Sponsored Research Administration
Temple, Texas
Scott & White Healthcare
Temple, Texas
Fundacion Argentina Contra las Enfermedades Neurologicas (FACENE)
Buenos Aires, Argentina
Clinic of Neurology,Clinical Centar University Sarajevo
Sarajevo, Bosnia and Herzegovina
MBAL Puls AD, Nevrologichno otdelenie
Blagoevgrad, Bulgaria
UMBAL Dr. Georgi Stranski, Vtora nevrologichna klinika
Pleven, Bulgaria
DKTs Akta Medika, Konsultativen kabinet po Nevrologiya
Sevlievo, Bulgaria
MBALNP Sveti Naum EAD, Klinika po nervni bolesti za paroksizmalnite sastoyaniya,
Sofia, Bulgaria
Vtora Mnogoprofilna Bolnitsa za Aktivno Lechenie, Nevrologichno Otdelenie
Sofia, Bulgaria
Litomyslská nemocnice, a.s.
Litomyšl, Czechia
Fakultni Thomayerova nemocnice s poliklinikou,Neurologicka klinika IPVZ/FTNsP
Prague, Czechia
Neurologicka ambulance
Prague, Czechia
Epilepsie-Zentrum Bethel
Bielefeld, Germany
Praxis fuer Neurologie und Psychiatrie, Psychotherapie
Bielefeld, Germany
Klinik fuer Epileptologie, Universitaet Bonn
Bonn, Germany
Neuro Consil GmbH
Düsseldorf, Germany
Showing 40 of 82 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.